Cullinan Therapeutics (CGEM) Non-Current Deffered Revenue (2020 - 2021)
Cullinan Therapeutics (CGEM) posted quarterly Non-Current Deffered Revenue of $65000.0 for Q4 2021, down 12.16% year-over-year from $74000.0 in Q4 2020, and down 2.99% quarter-over-quarter from $67000.0 in Q3 2021.
Powered by 
Analysis
Cullinan Therapeutics (CGEM) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Cullinan Therapeutics' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $65000.0 for Q4 2021.
- In Q4 2021, Non-Current Deffered Revenue fell 12.16% year-over-year to $65000.0; the TTM figure through Dec 2021 stood at $65000.0 (down 12.16% YoY), while the FY2021 annual figure was $65000.0, down 12.16% from the prior year.
- Non-Current Deffered Revenue for Q4 2021 stood at $65000.0, down from $67000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $74000.0 in Q4 2020, with the low at $65000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 10 | Cullinan Therapeutics | 1.37 Bn | 1.37 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 65,000.00 |
| Sep 30, 2021 | 67,000.00 |
| Jun 30, 2021 | 70,000.00 |
| Mar 31, 2021 | 73,000.00 |
| Dec 31, 2020 | 74,000.00 |